

**16<sup>th</sup> International Congress of TDM & Clinical Toxicology**  
**Brisbane, Australia**

---

**Immunosuppressive Drugs Scientific Committee Meeting**

**Monday 17, September 2018, 13:00-14:00**

**Minutes**

Attending members:

Loralie Langman, Pierre Marquet, Dennis A. Hesselink, Maria Shipkova, Eberhard Wieland, Tomasz Pawinski, Pawel Kunicki, Olga Millán, Dirk-Jan Moes, Stein Bergan, Mercè Brunet.

1. Mercè Brunet opened the meeting and welcomed all attending members of the Immunosuppressive Drugs Committee.
2. Mercè Brunet gave a brief summary of all the activities during 2017-2018 of Immunosuppressive Drugs Committee as well as the 3 Working Groups which belong to the Committee. This information is available on the website.

**3. Suggested projects 2018-2019**

**3.1. Consensus Documents**

Mercè Brunet as co-coordinator (with Stein Bergan) of the *Therapeutic Drug Monitoring of tacrolimus-personalized Therapy: Second Consensus Report*: informed about the status of this document, stating that due to an important delay in finishing some sections, the manuscript would be submitted before the end of 2018 and published in TDM Journal at the beginning of 2019.

**3.2. Participation in Symposiums and workshops**

All members attending participated in the contributions to the scientific program of **17th IATDMCT Congress, Iguazu 2019**. Proposals for plenary lectures, morning sessions, and a symposium on “TDM of Immunosuppressive Drugs-personalized therapy” have been send to the Organizing Committee.

Mercè Brunet talked about our future participation in the EuroMedLab Congress; SECQ&FLM Joint Scientific Meeting. Barcelona, May 2019. With a *Symposium on Personalized Immunosuppression to improve clinical outcomes*, which includes 3 lectures: *Monitoring tacrolimus intracellular concentrations, would it help better predicting graft clinical outcome?* by F. Lemaitre; *Pharmacogenetic Biomarkers Predictive of the Pharmacokinetics and Pharmacodynamics of ISDs* by T. van Gelder; and *The role of Biomarkers in Solid Organ Transplantation* by M. Brunet. Chairs: T. van Gelder and M. Brunet

This symposium will be a great opportunity for the dissemination of the Therapeutic Drug Monitoring of tacrolimus-personalized Therapy: Second Consensus Report.

### **3.3. Active participation in the Compass was considered.**

Members present discuss whether one or two articles on behalf of our Committee could be published per year. Some proposals on manuscripts were made for the next Compass Issues: *Therapeutic drug monitoring of Mycophenolic acid products: Evidence and Knowledge gaps, laboratory and clinical experience* by T. van Gelder, and *The generic formulations of immunosuppressive drugs and the role of TDM. The questions still current* by T. Pawinski & P. Kunicki.

3.4. Preparation and posting of educational materials on the Resources area of the IATDMCT website. M Shipkova.

## **4. New activities of the Working Groups of the Immunosuppressive Drugs Committee**

**Standardization of ISD TDM Working Group.** Leaders: Christoph Seeger, Loralie Langman

Loralie Langman talked in detail about the new standardization project of immunosuppressive drug monitoring. The analytical standardisation lead by Christoph Seger & Loralie Langman with the collaboration of the WG-ID that involves several members of our Committee and the IFCC. Loralie Langman also informed about the next WG-ID meeting that will take place in EuromedLab Congress in Barcelona, May 2019.